Related references
Note: Only part of the references are listed.Clinicopathological characteristics of intrahepatic cholangiocarcinoma according to gross morphologic type: cholangiolocellular differentiation traits and inflammation-and proliferation-phenotypes
Taek Chung et al.
HPB (2020)
Ivosidenib in IDH1-mutant, chemotherapy-refractory Croatia& cholangiocarcinoma (ClarlDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou-Alfa et al.
LANCET ONCOLOGY (2020)
Neoplastic Transformation of the Peribiliary Stem Cell Niche in Cholangiocarcinoma Arisen in Primary Sclerosing Cholangitis
Guido Carpino et al.
HEPATOLOGY (2019)
Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).
Milind M. Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics
Li Ding et al.
CELL (2018)
Oncogenic Signaling Pathways in The Cancer Genome Atlas
Francisco Sanchez-Vega et al.
CELL (2018)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention
Maeve A. Lowery et al.
CLINICAL CANCER RESEARCH (2018)
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Milind Javle et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
Christopher P. Wardell et al.
JOURNAL OF HEPATOLOGY (2018)
IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC
Jian Wang et al.
JOURNAL OF SURGICAL RESEARCH (2018)
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma
Michele Simbolo et al.
SCIENTIFIC REPORTS (2018)
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification
Julien Calderaro et al.
JOURNAL OF HEPATOLOGY (2017)
Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas
Masayuki Akita et al.
MODERN PATHOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging
Mahul B. Amin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Distinct Clinicopathologic and Genetic Features of 2 Histologic Subtypes of Intrahepatic Cholangiocarcinoma
Akimasa Hayashi et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management
Milind Javle et al.
CANCER (2016)
Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise
Supriya K. Saha et al.
ONCOLOGIST (2016)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models
Alexandre Doussot et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2015)
Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma
Lipika Goyal et al.
ONCOLOGIST (2015)
Intrahepatic Cholangiocarcinoma: expert consensus statement
Sharon M. Weber et al.
HPB (2015)
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies
Giovanni Brandi et al.
ONCOTARGET (2015)
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Andrew X. Zhu et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Fibroblast Growth Factor Receptor 2 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Cholangiocarcinoma
Yasuhito Arai et al.
HEPATOLOGY (2014)
Morphological subclassification of intrahepatic cholangiocarcinoma: etiological, clinicopathological, and molecular features
Jau-Yu Liau et al.
MODERN PATHOLOGY (2014)
Mutational landscape of intrahepatic cholangiocarcinoma
Shanshan Zou et al.
NATURE COMMUNICATIONS (2014)
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Yizhou Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers
Waraporn Chan-on et al.
NATURE GENETICS (2013)
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Yuchen Jiao et al.
NATURE GENETICS (2013)
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas
P. Wang et al.
ONCOGENE (2013)
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes
Mina Komuta et al.
HEPATOLOGY (2012)
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Benjamin R. Kipp et al.
HUMAN PATHOLOGY (2012)
Exome sequencing of liver fluke-associated cholangiocarcinoma
Choon Kiat Ong et al.
NATURE GENETICS (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment
Mechteld C. de Jong et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results?
Nancy E. Kemeny et al.
ONCOLOGY (2011)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival
W. R. Jarnagin et al.
ANNALS OF ONCOLOGY (2009)
Intrahepatic cholangiocardnoma - Rising frequency, improved survival, and determinants of outcome after resection
Itaru Endo et al.
ANNALS OF SURGERY (2008)
Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
Mina Komuta et al.
HEPATOLOGY (2008)
A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules: 'bile ductular carcinoma'
K. Kozaka et al.
HISTOPATHOLOGY (2007)
Proposal of progression model for intrahepatic cholangiocarcinoma: Clinicopathologic differences between hilar type and peripheral type
Shinichi Aishima et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States
T Patel
HEPATOLOGY (2001)
Share Paper
